Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysis.
Tian T, Li Y, Li J, Xu H, Fan H, Zhu J, Wang Y, Peng F, Gong Y, Du Y, Yan X, He X, Cali Daylan AE, Pircher A, Neibart SS, Okuma Y, Hong MH, Huang M, Lu Y. Tian T, et al. Among authors: hong mh. Transl Lung Cancer Res. 2024 Apr 29;13(4):861-874. doi: 10.21037/tlcr-24-116. Epub 2024 Apr 24. Transl Lung Cancer Res. 2024. PMID: 38736501 Free PMC article.
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.
Kim DK, Lee CY, Han YJ, Park SY, Han H, Na K, Kim MH, Yang SM, Baek S, Kim Y, Hwang JY, Lee S, Kang SS, Hong MH, Lim SM, Lee JB, Kim JH, Cho BC, Pyo KH. Kim DK, et al. Among authors: hong mh. Front Immunol. 2024 Apr 12;15:1330228. doi: 10.3389/fimmu.2024.1330228. eCollection 2024. Front Immunol. 2024. PMID: 38680496 Free PMC article.
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Na K, Lee S, Kim DK, Kim YS, Hwang JY, Kang SS, Baek S, Lee CY, Yang SM, Han YJ, Kim MH, Han H, Kim Y, Kim JH, Jeon S, Byeon Y, Lee JB, Lim SM, Hong MH, Pyo KH, Cho BC. Na K, et al. Among authors: hong mh. Front Immunol. 2024 Mar 7;15:1336246. doi: 10.3389/fimmu.2024.1336246. eCollection 2024. Front Immunol. 2024. PMID: 38515751 Free PMC article.
A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma.
Kim CG, Hong MH, Kim D, Lee BH, Kim H, Ock CY, Kelly G, Bang YJ, Kim G, Lee JE, Kim C, Kim SH, Hong HJ, Park YM, Sim NS, Park H, Park JW, Lee CG, Kim KH, Park G, Jung I, Han D, Kim JH, Cha J, Lee I, Kang M, Song H, Oum C, Kim S, Kim S, Lim Y, Kim-Schulze S, Merad M, Yoon SO, Kim HJ, Koh YW, Kim HR. Kim CG, et al. Among authors: hong mh. Clin Cancer Res. 2024 Mar 8. doi: 10.1158/1078-0432.CCR-23-3249. Online ahead of print. Clin Cancer Res. 2024. PMID: 38457288
447 results